AbbVie's shared lymphoma drug Epkinly wins a late-stage trial

Genmab said Epkinly, a lymphoma drug it splits equally with AbbVie (ABBV), cut the risk of disease progression or death by 51% alongside chemotherapy in a Phase 3 trial of previously untreated patients. Genmab's ovarian cancer drug Rina-S also won a Phase 3 trial. Barclays sees it as an option for patients who can't take AbbVie's Elahere or whose cancer grew after it. John Hickenlooper holds AbbVie.

Sources

Genmab Doubles in Three Months on Three Phase 3 Cancer Wins in October, Led by Petosemtamab; Q3 Earnings Due Nov 5
The whole story · updated
CN
CNBC
·
A little-known biotech’s high-stakes cancer bet just paid off and its shares doubled

The whole feed is waiting

Sign in to read every post and follow wallets.
Sign in